Clinical implication of PRAME immunohistochemistry in differentiating melanoma in situ and dysplastic nevus in non‐acral nevus‐associated melanoma in situ: An institutional experience and meta‐analysis
Journal of Cutaneous Pathology · 2024
DOI: 10.1111/cup.14671 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of Cutaneous Pathology, 2024. Verfasst von Chau M Bui und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Rochester Medical Center, Rochester, New York, USA. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Dysplastic Nevus Syndrome, Antigens, Neoplasm. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Introduction
PReferentially expressed Antigen in MElanoma (PRAME) has shown utility in differentiating benign from malignant melanocytic neoplasms. In this study, we investigated the clinical significance of PRAME expression in dysplastic nevi (DN) and nevus‐associated melanoma in situ (MIS).
Methods
We included 172 DN and 38 nevus‐associated MIS from our institutional archive. PRAME positive expression was defined as nuclear staining in at least 75% of melanocytes. In addition, relevant studies from PubMed and Web of Science were incorporated into a meta‐analysis using the random‐effects model to assess PRAME expression in MIS and DN.
Results
Our institutional data revealed that 71.1% of nevus‐associated MIS cases exhibited positive PRAME expression in the MIS components, whereas all DN components were negative for PRAME. 5.7% of cases diagnosed as DN in our cohort demonstrated diffuse positivity for PRAME. Notably, MIS associated with DN displaying epidermal and dermal components displayed a higher likelihood of PRAME positivity compared to those arising on a background of DN with solely epidermal (junctional) components (84% vs. 46%, p = 0.024). The meta‐analysis indicated that the pooled PRAME positivity in MIS and DN was 54.5% and 1.9%, respectively.
Conclusion
PRAME is a valuable immunohistochemical marker for differentiating MIS from DN, particularly in the context of nevus‐associated MIS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Rochester Medical Center, Rochester, New York, USA.
- Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
- Department of Pathology, University of Yamanashi, Chuo, Yamanashi, Japan.
- Department of Dermatology, University of Rochester Medical Center, Rochester, New York, USA.
ORCID-Profile: Bruce R Smoller
Zitieren
APA
Bui, C. M., Vuong, H. G., Le, M. K., D'Angelo, J., Mannava, K., & Smoller, B. R. (2024). Clinical implication of PRAME immunohistochemistry in differentiating melanoma in situ and dysplastic nevus in non‐acral nevus‐associated melanoma in situ: An institutional experience and meta‐analysis. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.14671
Vancouver
Bui CM, Vuong HG, Le MK, D'Angelo J, Mannava K, Smoller BR. Clinical implication of PRAME immunohistochemistry in differentiating melanoma in situ and dysplastic nevus in non‐acral nevus‐associated melanoma in situ: An institutional experience and meta‐analysis. Journal of Cutaneous Pathology. 2024. doi:10.1111/cup.14671
BibTeX
@article{Bui2024,
author = {Bui, Chau M and Vuong, Huy Gia and Le, Minh-Khang and D'Angelo, Josephine and Mannava, Kathleen and Smoller, Bruce R},
title = {Clinical implication of PRAME immunohistochemistry in differentiating melanoma in situ and dysplastic nevus in non‐acral nevus‐associated melanoma in situ: An institutional experience and meta‐analysis},
journal = {Journal of Cutaneous Pathology},
year = {2024},
doi = {10.1111/cup.14671}
}
EUVIMED